Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and ... including Vertex Pharmaceuticals’ $4.9 billion ...

The drugs show pharma at its best and its worst: drugs such as Vertex's Orkambi and Novartis ... EMA in September), both cut LDL cholesterol by more than 60% in hard-to-treat patients, but ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price dropped by Piper Sandler from $535.00 to $533.00 in a report released on Monday,Benzinga reports. The firm currently h ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Vertex Pharmaceuticals (VRTX – ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

Vertex Pharmaceuticals (VRTX ... With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our ...